News

Lilly will continue global launches despite MFN pricing uncertainty, Japan price cuts, and rising obesity-drug competition.

U.S. and Iranian negotiators agreed on a 60-day memorandum of understanding to extend the ceasefire, media reports suggested.

Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Reddit Stocks to Buy According to Billionaires. On May 26, Reuters reported that Eli Lilly and Company (NYSE:LLY) plans to acquire three vaccine developers in deals worth up to $3.8 billion combined, marking a deeper push into infectious disease prevention. The US drugmaker said […]

The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged.

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.

CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug business.

CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

The S&P 500 and Nasdaq Composite were up, while the Dow Jones Industrial Average was down slightly i

Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would add the company’s obesity treatment Zepbound to its preferred drug formulary. Lilly said the decision means all three of the largest pharmacy benefit managers in the United States will now provide coverage for the company’s full obesity medicine portfolio.

Eli Lilly and Company (NYSE:LLY) is included among the 10 Safe Stocks to Buy for the Long Term in 2026. On May 26, BofA raised the firm’s price recommendation for Eli Lilly and Company (NYSE:LLY) to $1,251 from $1,133. It reiterated a Buy rating on the shares. The firm said it expects Lilly’s future revenue […]

With a five-year EPS forecast of 28.38%, Eli Lilly and Company (NYSE:LLY) is among the 12 Best Future Stocks to Buy Right Now. On May 21, Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 data for retatrutide that demonstrated weight loss of up to 26.1% at 80 weeks and more than 30% at 104 weeks in […]

We recently compiled a list of the 10 Most Widely Held Stocks by Individuals in 2026. Eli Lilly and Company (NYSE:LLY) is also one of the most widely held stock by individuals. TheFly reported on May 21 that Wolfe Research maintained an Outperform rating on LLY and kept its $1,350 price target unchanged. The firm […]

Small biotech firms "latch onto" AI more quickly than bigger firms, the head of ‌Chinese tech giant Tencent's healthcare division said on ‌Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly ​turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk ‌and Eli Lilly have ⁠announced AI-related collaborations with technology firms.

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.

Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.

There is no reason to panic just yet.

Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.

There’s a tech ETF that has been almost neck-and-neck with the S&P 500 in the past year and has built up a meaningful lead over the past five years. It’s the Vanguard’s Mega Cap Growth ETF (NYSEARCA:MGK). This ETF tracks the price of the CRSP US Mega Cap Growth Index, which in turn tracks companies ... Buy, Sell, or Hold Vanguard’s Mega Cap Growth ETF Right Now | MGK

Eli Lilly's fundamentals matter more than Trump's stock purchases.

Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.

LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.

Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.